Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $10.00

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have received a consensus rating of “Buy” from the five analysts that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.50.

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Piper Sandler lowered their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th.

Institutional Trading of Century Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC boosted its stake in Century Therapeutics by 56.0% in the 4th quarter. Squarepoint Ops LLC now owns 164,871 shares of the company’s stock worth $167,000 after purchasing an additional 59,174 shares in the last quarter. Two Sigma Investments LP purchased a new position in Century Therapeutics during the 4th quarter worth approximately $67,000. Two Sigma Advisers LP purchased a new position in Century Therapeutics during the 4th quarter worth approximately $52,000. Nuveen Asset Management LLC raised its position in Century Therapeutics by 48.9% during the 4th quarter. Nuveen Asset Management LLC now owns 157,311 shares of the company’s stock worth $159,000 after buying an additional 51,661 shares during the last quarter. Finally, Millennium Management LLC raised its position in Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock worth $1,623,000 after buying an additional 1,466,415 shares during the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Price Performance

IPSC stock opened at $0.63 on Thursday. The company has a market capitalization of $53.17 million, a PE ratio of -0.34 and a beta of 1.75. Century Therapeutics has a 12 month low of $0.55 and a 12 month high of $5.24. The firm’s 50-day moving average is $0.78 and its 200 day moving average is $1.19.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.